Rubens R D, King R J, Sexton S, Minton M J, Hayward J L
Cancer Chemother Pharmacol. 1980;4(1):43-5. doi: 10.1007/BF00255457.
Of 54 patients with advanced breast cancer, 21/37 (57%) with oestrogen receptor-positive (ER+) tumours and 11/17 (65%) with oestrogen receptor-negative (ER-) tumours responded to cytotoxic chemotherapy. These data and a survey of the literature indicate that oestrogen receptor status is not a determinant of response to chemotherapy. However, ER+ tumours seem to grow more slowly than ER- ones and the response to chemotherapy tends to be longer in ER+ patients.
在54例晚期乳腺癌患者中,37例雌激素受体阳性(ER+)肿瘤患者中有21例(57%)、17例雌激素受体阴性(ER-)肿瘤患者中有11例(65%)对细胞毒性化疗有反应。这些数据以及文献调查表明,雌激素受体状态不是化疗反应的决定因素。然而,ER+肿瘤似乎比ER-肿瘤生长得更慢,并且ER+患者对化疗的反应往往持续时间更长。